Description
+ Include: 45 videos + 2 pdfs, size: 12.4 GB
+ Target Audience: physicians, nurse practitioners (NPs), and physician assistants (PAs) interested in changes and advances impacting the care of patients who have or are at risk for thrombotic disorders
+ Sample video: contact me for sample video
+ Information:
DATE OF ORIGINAL RELEASE: December 31, 2022
ESTIMATED TIME TO COMPLETE: 12 hours to complete the activity.
TARGET AUDIENCE:
This educational activity was designed for physicians, nurse practitioners (NPs), and physician assistants (PAs) interested in changes and advances impacting the care of patients who have or are at risk for thrombotic disorders.
LEARNING OBJECTIVES:
At the completion of this course, you should be able to:
• Identify the etiology and pathophysiology of atherothrombosis
• Recognize the link between inflammation and thrombotic illnesses
• Explain new tools for stroke prevention (and stroke prediction) in atrial fibrillation
• Identify the optimal duration of anticoagulation for PE and DVT
• Provide advanced therapy beyond anticoagulation in PE and DVT: thrombolysis, catheterdirected therapy, surgical embolectomy
• Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
• Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
• Manage a high-risk pregnancy
+ Topics:
1. What’s New with TG & AngPTL3.mp4
2. What’s New with Lp(a).mp4
3. What’s New with LDL & ApoB.mp4
4. What’s New with Inflammatory Targets.mp4
5. Discussion, Q&A.mp4
6. PAD – Pathways for Optimizing Cardiovascular & Limb Outcomes.mp4
7. Discussion, Q&A.mp4
8. Heart Failure & Venous Thromboembolism.mp4
9. More Than Just Diabetes & Heart Failure – SGLT2.mp4
10. More Than Just Diabetes & Heart Failure – GLP1.mp4
11 Heart Failure – Reduced Ejection Fraction.mp4
12. Discussion, Q&A.mp4
13. Heart Failure – Preserved Ejection Fraction.mp4
14. Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup.mp4
15. CMR Imaging of Heart Failure.mp4
16. Dual Antiplatelet Therapy & Anticoagulation.mp4
17. How to Manage the Anticoagulation Around Ablation & Cardioversions & Watchmans for AF.mp4
18. Dose-Reduced Direct Oral Anticoagulants – Efficacy & Safety.mp4
19. Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data & Variations in Practice.mp4
20. Duration of Anticoagulation – Venous Thrombosis.mp4
21. Novel Anticoagulation Targets – Factor XI & XII Inhibitors.mp4
22. Discussion, Q&A.mp4
23. Racial Disparities in Healthcare.mp4
24. Racial Disparities in Arterial & Venous Thrombosis.mp4
25. Discussion, Q&A.mp4
26. VTE Prediction – Using Genetics as a Powerful Tool.mp4
27. Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD.mp4
28. Discussion, Q&A.mp4
29. COVID & Thrombosis – Mechanisms & Epidemiology.mp4
30. Prevention of VTE in COVID-19 Patients.mp4
31. Discussion, Q&A.mp4
32. VTE Prophylaxis for Orthopaedic Surgery.mp4
33. Discussion, Q&A.mp4
34. Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape.mp4
35. Systemic Fibrinolysis (PEITHO-3).mp4
36. Adventures with Hypertrophic Cardiomyopathy – 1958-2022.mp4
37. Chronic Thromboembolic Pulmonary Hypertension.mp4
38. Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension.mp4
39. Post-thrombotic Syndrome – Epidemiology & Medical Therapy.mp4
40. Intervention, Acute Intervention & Chronic Venous Obstructive Disease.mp4
41. Discussion, Q&A.mp4
42. Vascular Cardio-Oncology.mp4
43. Prevention of Thrombotic Complications of Cancer & Cancer Therapy.mp4
44. Treatment of Cancer-Associated Thrombosis.mp4
45. Discussion, Q&A.mp4
Questions.pdf
Syllabus.pdf
Reviews
There are no reviews yet.